BioSpace News Archive

On March 28, 2024, Orexo AB, successfully issued senior secured callable floating rate social bonds in an amount of SEK 500 million and with a tenor of four years.

CorMedix Inc. today announced that management will be participating in fireside chats and investor meetings at both the JMP Securities Life Sciences Conference being held in New York on May 13 – 14, 2024 and the 2024 RBC Capital Markets Global Healthcare Conference being held in New York.

Citius Pharmaceuticals, Inc. today announced its participation in two upcoming investor conferences.

Artelo Biosciences, Inc. today announced that it will be participating in the 2024 Pharma Partnering Summit being held May 14th – 15th in San Diego, California.

QT Imaging Holdings, Inc. (NASDAQ: QTI) (“QT Imaging” or the “Company”), a medical device company engaged in research, development, and commercialization of innovative body imaging systems, today announced financial results for the first quarter of 2024.

Immix Biopharma, Inc. today announced new clinical data from its Phase 1b/2a NEXICART-1 (NCT04720313) study of novel, autologous, sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy, NXC-201, in patients with relapsed/refractory AL Amyloidosis (R/R ALA) in a late breaking oral presentation at the 27th Annual Meeting of The American Society of Gene and Cell Therapy (ASGCT) in Baltimore, MD.

On April 29th, 2024, the U.S. FDA granted full approval for Seagen Inc.'s TIVDAK® (tisotumab vedotin) targeting tissue factor (TF) for the treatment...

Cardiologist Brendan Carry, MD, and a team of Geisinger physicians have enrolled the first patient in the U.S. into a cardiac amyloidosis trial.

According to recent study by nova one advisor, the U.S. gene synthesis market size reached USD 700.90 million in 2023 and is projected to hit around USD 3,118.73 million by 2033, expanding at a CAGR of 16.1% from 2024 to 2033.

Novavax, Inc., a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, announced its financial results and operational highlights for the first quarter ended March 31, 2024.